AS703569 Phase I in Patients With Solid Tumours

A Phase I Multicenter, Open-Label, Dose Escalation Trial of AS703569 Given Orally to Subjects With Solid Tumours

This is a Phase I trial. Some specific protocol information is proprietary and is not publicly available at this time. Full information will be provided to trial participants.

Study Overview

• Status: Completed
• Conditions: Solid Tumors
• Intervention / Treatment: Drug: AS703569; Drug: AS703569; Drug: AS703569

• Study Type: Interventional
• Enrollment (Actual): 104
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Massachusetts
    • Rockland, Massachusetts, United States, 02370
      • EMD Serono Medical Information Office

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Histopathologically confirmed locally advanced or metastatic solid tumour that is either refractory after standard of care therapy for the disease or for which standard of care therapy is not reliably effective or has a cancer for which no standard therapy exists
2. Age greater than or equal to 18 years
3. Has read and understands the informed consent form and is willing and able to give informed consent, and subject authorization under Health Insurance Portability and Accountability Act (HIPAA). Fully understands requirements of the study and willing to comply with all study visits and assessments
4. Subjects and their partners must be willing to avoid pregnancy during the study and until 1 month after the last study drug administration. Males with female partners of childbearing potential and female subjects of childbearing potential must therefore be willing to use adequate contraception such as, intra uterine device, diaphragm, or condom, for the duration of the study. For the purposes of this study, childbearing potential is defined as: "All female subjects unless they are post- menopausal for at least two years, are surgically sterile or sexually inactive"
5. Negative serum pregnancy test at the screening visit for women of childbearing potential

Exclusion Criteria:

1. Bone marrow impairment as evidenced by Hb < 9.0 g/dl, ANC < 1.5x 109/L, platelets < 75 x 109/L. Subjects may be transfused.
2. Renal impairment as evidenced by serum creatinine > 1.5 x ULN (upper limit of normal), and/or calculated creatinine clearance < 60 ml/min
3. Liver function abnormality as defined by total bilirubin > 1.5 ULN, or AST or ALT > 2.5x ULN at screening; for subjects with liver involvement AST or ALT > 5x ULN at screening
4. INR (blood coagulation) > 1.5 x ULN for subjects not on therapeutic doses of coumadin
5. History of CNS metastases, unless subject has been previously treated for CNS metastases, is stable by CT scan without evidence of cerebral edema, and has no requirements for corticosteroids or anticonvulsants
6. History of difficulty swallowing, malabsorption or other chronic gastro- intestinal disease or conditions that may hamper compliance and/or absorption of the tested product
7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) > 2
8. Known HIV, hepatitis C, or hepatitis B positivity
9. Has received chemotherapy, immunotherapy, hormonal therapy, biologic therapy, or any other anticancer therapy or surgical intervention within 28 Days of Day 1 of study drug treatment (6 weeks for nitrosureas or mitomycin C), and must have fully recovered
10. Has received extensive prior radiotherapy on more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation
11. Has received any investigational agent within 28 days of Day 1
12. Has history of any other significant medical disease or intervention including major gastric or small bowel surgery or has a psychiatric condition that might impair the subjects well-being or preclude full participation in the study
13. Is a pregnant or nursing female

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: 1; Regimen 1	Drug: AS703569; Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle; Other Names: Aurora kinase inhibitor; MSC1992371A; Drug: AS703569; Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle; Other Names: Aurora kinase inhibitor; MSC1992371A; Drug: AS703569; Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle; Other Names: Aurora kinase inhibitor; MSC1992371A
Active Comparator: 2; Regimen 2	Drug: AS703569; Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle; Other Names: Aurora kinase inhibitor; MSC1992371A; Drug: AS703569; Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle; Other Names: Aurora kinase inhibitor; MSC1992371A; Drug: AS703569; Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle; Other Names: Aurora kinase inhibitor; MSC1992371A
Active Comparator: 3; Regimen 3	Drug: AS703569; Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle; Other Names: Aurora kinase inhibitor; MSC1992371A; Drug: AS703569; Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle; Other Names: Aurora kinase inhibitor; MSC1992371A; Drug: AS703569; Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle; Other Names: Aurora kinase inhibitor; MSC1992371A

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number and proportion of subjects experiencing: at least a Dose-Limiting Toxicity (DLT) in each cohort during the first cycle.	Undefined

Secondary Outcome Measures

Outcome Measure	Time Frame
Plasma and urine PK parameters of AS703569, genetic markers and potential markers of clinical and biological response.	Undefined
Number and proportion of subjects with Progressive Disease as assessed at the end of every other cycle.	Undefined

Collaborators and Investigators

• Sponsor: EMD Serono
• Investigators: Study Director: Narmyn Rejeb, MD, Merck Serono S.A., Geneva

Publications and helpful links

General Publications

• Mita M, Gordon M, Rejeb N, Gianella-Borradori A, Jego V, Mita A, Sarantopoulos J, Sankhala K, Mendelson D. A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors. Target Oncol. 2014 Sep;9(3):215-24. doi: 10.1007/s11523-013-0288-3. Epub 2013 Jul 6.

Study record dates

Study Major Dates

• Study Start: August 1, 2006
• Primary Completion (Actual): June 1, 2010
• Study Completion (Actual): June 1, 2010

Study Registration Dates

• First Submitted: October 20, 2006
• First Submitted That Met QC Criteria: October 23, 2006
• First Posted (Estimate): October 24, 2006

Study Record Updates

• Last Update Posted (Estimate): January 30, 2014
• Last Update Submitted That Met QC Criteria: January 29, 2014
• Last Verified: January 1, 2014

More Information

Terms related to this study

• Keywords: Oncology. All solid Tumour disease.
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: 26865